Rapivab is an intravenous (IV) treatment indicated in the US for acute uncomplicated influenza in adults aged 18 years and older. bioCSL general manager and senior vice-president Dr
As part of the deal, the two firms will carry out collaborative research using the J-Brain Cargo technology and certain pharmaceutical candidate compounds of Sumitomo’s choice, with a
As part of the deal, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. The company
The collaboration is aimed to advance understanding of the biological mechanisms that underpin these conditions and develop new treatments based on this knowledge. As part of the deal,
The company was also notified by FDA’s regulatory advisors to proceed with the clinical trial of its investigational universal flu vaccine. The IND application will allow the company
The transaction, valued at $75 per Kythera share, is subject to the fulfillment of certain customary conditions. According to the company, the fixed-value transaction consideration will be payable
Currently, PUR0200 is being evaluated for chronic obstructive pulmonary disease (COPD) and the first small molecule formulation from Pulmatrix’s new iSPERSE inhaled dry powder technology. PUR0200, which contains
Both these HPV types are responsible for 70% of cervical cancer cases and currently there are no treatment options available for the 93 million women worldwide infected with
Earlier, the agency has accepted the company’s investigational new drug (IND) application for a Phase I/II open-label, dose-escalating trial of PRTX-100 in adults with persistent/chronic ITP. The company
Dextenza (sustained release dexamethasone, 0.4mg) is administered by a physician as a bioresorbable intracanalicular depot for drug release to the ocular surface for up 30 days. People who
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.